Canadian Pacific Kansas City Limited Common Shares vs Danaher Corporation — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $83.86 (market cap $73.71B), while Danaher Corporation trades at $217.88 (market cap $153.60B). The key difference: Danaher Corporation is far larger — about 2.1× Canadian Pacific Kansas City Limited Common Shares's market cap, and Canadian Pacific Kansas City Limited Common Shares pays the higher dividend (0.91%). Which is the better fit depends on your goals.
| CP | DHR | |
|---|---|---|
Market Cap | $73.71B | $153.60B |
Volume | 2,143,178 | 3,974,063 |
Sector | Industrials | Health |
52-Week High | $96.69 | $242.05 |
52-Week Low | $68.88 | $161.91 |
Enterprise Value | $91.14B | $175.81B |
Dividend Yield | 0.91% | 0.73% |
Typical Hold Time | — | 69 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →